TNFRSF8 and Hodgkins lymphoma: The drug is approved for the treatment of relapsed or refractory CD30-positive classical Hodgkin’s lymphoma (HL), as consolidation therapy after autologous hematopoietic stem cell transplantation in HL, and for relapsed or refractory anaplastic large T-cell lymphoma (ALCL) [14].